John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.